Tiago Girão serves as Chief Financial Officer at Immunovant Inc., where he oversees the company’s financial strategy, capital allocation, and reporting functions in support of its mission to develop targeted therapies for autoimmune diseases. In this role, he manages investor relations, ensures compliance with regulatory requirements, and drives initiatives to optimize operational efficiency as the clinical-stage biotechnology firm advances its pipeline, including lead candidate IMVT-1401. Prior to joining Immunovant, Girão accumulated extensive experience in the life sciences sector, holding senior finance positions at several publicly traded biopharmaceutical companies. His career includes expertise in fundraising through equity offerings and strategic partnerships, as well as implementing robust financial controls during periods of rapid growth and clinical expansion. Girão’s achievements encompass successfully guiding multiple organizations through complex financing rounds that have funded late-stage clinical trials and commercial preparations. At Immunovant, he has contributed to strengthening the balance sheet and positioning the company for sustainable long-term value creation amid evolving market dynamics in the autoimmune therapeutics space.